arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

MapLight Therapeutics, Inc.

MPLT

$12.17 ▼ -1.11 (-8.36%) at close

10 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

MapLight Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $551.0M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -12.7% ↗

FCF / Share $-1.13

Trailing P/E —

Price / Book 1.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-60.67M

↓ -171.6% —

FCF / Share Free cash flow per share

$-1.13

↑ +96.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
EPS Growth YoY (%)	95.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	-48.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-171.6% Weak ↓ Weak Declining Year-over-year change in net income	-274.7% Weak Weak Year-over-year change in net income	-18.0% Weak Weak Year-over-year change in net income	—	—	—	—	—	—	—
FCF Growth YoY (%)	96.6% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
FCF / Net Income (x)	0.84x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.59x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	1.14x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Return on Invested Capital (%)	-12.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-14.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	9.1% Fair → Fair Stable Return earned on debt + equity capital invested Optimal: > 10%	—	8.6% Fair ↓ Fair Declining Return earned on debt + equity capital invested Optimal: > 10%	9.3% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	9.6% Fair Fair Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-15.4% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-17.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-12.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-16.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-15.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-201%)	-17.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-216%)	8.1% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-46%)	—	10.4% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-31%)	11.0% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-27%)	11.0% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-27%)	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Net Debt (USD)	$-55.71M	$-46.73M	$-64.15M	—	—	$-38.25M	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Basic EPS, GAAP (USD)	$-1.34	$87.14	$-37.18	—	$-29.33	$-28.01	$-25.08	—	—	—
Free Cash Flow per Share (USD)	$-1.13	—	—	—	$-33.55	—	—	—	—	—
Book Value per Share (USD)	$8.84	$10.41	$-339.32	—	$-283.39	$-254.35	$-227.34	—	—	—
Tangible Book Value per Share (USD)	$8.84	$10.41	$-339.32	—	$-283.39	$-254.35	$-227.34	—	—	—
Basic Weighted Avg Shares (shares)	45.28M	—	791,127	—	761,598	—	758,204	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Working Capital (USD)	$312.94M	$308.44M	$226.74M	—	—	$98.68M	—	—	—	—
Total Equity (USD)	$399.83M	$458.37M	$-274.18M	$-245.06M	$-215.83M	$-193.63M	$-172.37M	$-154.33M	$-136.00M	$-117.58M

📋 What is driving earnings? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Depreciation Expense (USD)	$162.00K	$140.00K	$100.00K	—	$166.00K	$194.00K	$200.00K	—	—	—
Net Income, GAAP (USD)	$-60.67M	$-79.55M	$-22.34M	—	$-22.34M	$-21.23M	$-18.93M	—	—	—
Operating Cash Flow (USD)	$-51.18M	$-46.83M	—	—	$-25.55M	$-21.49M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 10 quarters

MapLight Therapeutics, Inc.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MPLT with peers